The National Institute of Health guidelines recommend against the use of chloroquine or hydroxychloroquine for the treatment of coronavirus (COVID)-19, except in the setting of a clinical trial. No agent given before or after an exposure to COVID-19 is known to be effective in preventing the infection. Agents for pre or post-exposure prophylaxis are only advised in the setting of a clinical trial.
The Food and Drug Administration has not approved any drugs for the treatment of COVID-19, and has revoked the emergency use authorization of chloroquine and hydroxychloroquine. 
Current clinical management includes infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated. 
Infectious Diseases Society of America (IDSA) guidelines recommend that hydroxychloroquine be used in COVID-19 patients only in the context of a clinical trial. 
Hydroxychloroquine is recommended to be used for COVID-19 in the context of a carefully constructed randomized clinical trial, with a strong focus on the costs and benefits involved. 
A meta-analyses of 26 studies looked at clinical or observational trials exploring the effects of hydroxychloroquine treatment for COVID-19 patients. The meta-analyses demonstrated that there was no clinical benefit seen with hydroxychloroquine with or without azithromycin for COVID-19 patients.